Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 5/20 | 0.44 |
| ▸ | KDR | P35968 | 6/20 | 0.44 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 5/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | FLT1 | P17948 | 2/20 | 0.42 |
| ▸ | FLT4 | P35916 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24009188 | 0.81 | IRAK4 (0.47) | IRAK4KDREPHA2EPHB4ERBB2 | |
| SCHEMBL24010114 | 0.81 | KDR (0.58) | IRAK4ENPP1KDREPHA2EPHB4 | |
| SCHEMBL24010115 | 0.78 | ENPP1 (0.48) | IRAK4ENPP1KDREGFRFGFR1 | |
| SCHEMBL30288433 | 0.73 | PIK3CD (0.55) | ENPP1KDREPHA2EPHB4ERBB2 | |
| SCHEMBL24010104 | 0.73 | PIK3CD (0.55) | ENPP1KDREPHA2EPHB4ERBB2 | |
| Hydrochloric Acid SCHEMBL8809882 | 0.73 | IRAK4 (0.50) | IRAK4ENPP1KDREPHA2EPHB4 | |
| SCHEMBL3340933 | 0.71 | PIK3CD (0.64) | IRAK4KDREPHA2EPHB4ERBB2 | |
| SCHEMBL24008898 | 0.71 | ACHE (0.47) | ENPP1ACHEBACE1MAPK1 | |
| SCHEMBL24009040 | 0.70 | MET (0.43) | IRAK4KDR | |
| SCHEMBL16760390 | 0.70 | ENPP1 (0.68) | ENPP1KDREPHA2EPHB4ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2021225969-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | IRAK4 2820/4885ENPP1 1/4885KDR 3654/4885 |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | ENPP1, ENPP3, SMPD1 | IRAK4 2820/4885ENPP1 1/4885KDR 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.